ANKİLOZAN SPONDİLİT HASTALARINDA SERUM IL-8 DÜZEYİ VE HASTALIK AKTİVİTESİ İLE İLİŞKİSİ

Year 2008, Volume: 9 Issue: 2, 21 - 24, 01.08.2008

Yasemin Turan Serpil Bal Serpil Karayağız Alev Gürgan

Abstract

Amaç:Ankilozan spondilit (AS) başlıca sakroiliak eklem ve lomber omurga olmak üzere aksiyel iskelettutulumu ile giden kronik inflamatuar bir hastalıktır. Hastalığın patogenezinden sitokinlerin sorumlu olabileceğidüşünülmektedir. Bu çalışmanın amaçlarını AS'li hastalarda serum IL-8 düzeylerinin belirlenmesi ve IL-8düzeyleri ile hastalık aktivitesi arasındaki ilişkinin saptanması oluşturmaktadır.Gereç ve Yöntem:Modifiye New York kriterlerine göre AS tanısı almış 28 hasta çalışmaya dahil edildi.Hastaların klinik değerlendirilmelerinde BASDAI, BASFİ, BASMİ ve Maastricht Ankylosing SpondylitisEnthesis Score (MASES) indeksleri kullanıldı. ELISAyöntemi ile serum IL-8 düzeyleri ölçüldü.Bulgular: Hastaların ortalama yaş ve hastalık süreleri sırasıyla 35,4±10,8 yıl ve 75±97,1 ay olarak saptandı.Serum IL-8 düzeyleri ortalama 67,3±22,9 pg/mL olarak ölçüldü. Serum IL-8 düzeyinin diğer klinik ve laboratuarparametreler ile karşılaştırılmasında, sadece C-reaktif protein düzeyi (P=0,048) ve BASDAI (P=0,005) ileanlamlı ilişki gösterdiği gözlendi.Sonuç: BASDAI ve CRP AS'li hastaların klinik aktivitelerini değerlendirmede kullanılan iki önemliparametredir. Bu çalışmada saptanan serum IL-8 ile BASDAI ve CRP arasındaki ilişki serum IL-8 düzeylerininhastalık aktivitesinin takibinde kullanılabilecek objektif bir belirteç olduğunu gösterebilir

Keywords

Ankilozan spondilit, hastalık aktivitesi, interlökin-8

Correlation Between Serum IL-8 Levels and Disease Activity in Patients With Ankylosing Spondylitis

Abstract

Objective: Ankylosing Spondylitis (AS) is a chronic inflammatory disorder of the axial skeleton, affecting mainly the sacroiliac joints and the lumbar spine. Cytokines are believed to be responsible for the pathogenesis of the disease. The aims of this study were to determine serum interleukin-8 (IL-8) levels inAS patients and also to determine the relationship between these levels and disease activity. Materials and Methods: Twenty-eight patients with a diagnosis of AS according to the modified New York criteria were included in this study. BASDAI, BASFI, BASMI and Maastricht Ankylosing Spondylitis Enthesis Score (MASES) indexes were used for clinical evaluation of the patients. Serum IL-8 levels were measured by ELISA. Results: The mean age and disease duration of the patients were 35.4(10.8) years and 75(97.1) months respectively. The mean serum IL-8 level was 67.3(22.9) pg/mL. Among the evaluated clinical and laboratuary parameters a significant correlation was observed only between serum IL-8 levels and CRP (p=0,048) and also BASDAI(P=0,005). Conclusion: BASDAI and CRPare two important clinical parameters which are used in the evaluation of disease activity inAS patients. Finding a significant relationship between serum IL-8 level and these two parameters may indicate that serum IL-8 level could be used as an objective marker to monitor the disease activity inASpatients.

Keywords

Ankylosing spondylitis, disease activity, interleukin-8

References

• 1. Van der Linden S, Van der Heijde D, Braun J. Spondyloarthropathies: Ankylosing spondylitis. Kelley's textbook of rheumatology, seventh edition, Harris ED (ed), Elsevier, Philadelphia, 2005 : 1125-42.
• 2. Bal A, Unlu E, Bahar G, Aydog E, Eksioglu E, Yorgancioglu R. Comparison of serum IL-1ß, Sil-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 2007; 26: 211-5.
• 3. Gratacos J, Filella X, Sanmarti R, Canete J, Llena J, Molina R, et al. Serum cytokines (IL-6, TNF-alpha, IL- 1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 1994; 33(10): 927-31.
• 4. Sonel B, Tutkak H, Düzgün N. Serum levels of IL-1 beta, TNF-alpha, IL-8, and acute phase proteins in seronegative spondyloarthropathies. Joint Bone Spine 2002; 69: 463-7.
• 5. Toussirot E, Lafforgue P, Boucraut J, Despieds P, Schina A, Bernard D, et al. Serum levels of interleukin 1-beta, tumor necrosis factor-alpha, soluble interleukin 2 recetor and soluble CD8 in seronegative spondyloarthropathies. Rheumatol Int 1994; 13(5): 175-80.
• 6. Kumar V. Basic pathology. 5th edition: W.B. Saunders, Philadelphia, 1995: 25-40.
• 7. Roitt I, Brosstoff J, Male D. Immunology. Fourth edition: Mosby, London: 1998.
• 8. Lin E, Calvono E, Lowry SF. Inflammatory cytokines and cell response in surgery. Surgery 2000; 127(2):117- 26.
• 9. Rot A. Endothelial cell binding of NAPI/IL-8: Role in neutrophil migration. Immunol Today 1992; 51: 236- 65.
• 10. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for the modification of the New York criteria. Arthritis Rheum 1984; 27: 3618.
• 11. Garrett SL, Jenkinson TR, Kennedy LG, Kennedy LG, Whitelock HC, Gaisford P, et al. A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol 1994; 21: 2286-91.
• 12. Akkoç Y, Karatepe AG, Akar S, Kirazli Y, Akkoc N. A Turkish version of the bath ankylosing spondylitis disease activity index: reliability and validity. Rheumatol Int 2005; 25(4): 280-4.
• 13. Calin A, Garrett SL, Whitelock HC, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index (BASFI). J Rheumatol 1994; 21:2281-5.
• 14. Yanik B, Gursel YK, Kutlay S, Ay S, Elhan AH. Adaptation of the Bath Ankylosing Spondylitis Functional Index to the Turkish population, its reliability and validity: functional assessment in AS. Clin Rheumatol 2005; 24(1): 41-7.
• 15. Jenkinson TR, Mallorie P A, Whitelock H C, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis(AS). The bath AS metrology index. J Rheumatol 1994; 21: 1694-8.
• 16. Dorenbosch LH, Spoorenberg A, Van Tubergen A. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003; 62:127-32.
• 17. van der Linden S, van der Heijde D. Clinical aspects, outcome assessment, and management of ankylosing spondylitis and postenteric reactive arthritis. Curr Opin Rheumatol 2000; 12(4): 263-8.
• 18. Rashid T, Ebringer A. Ankylosing spondylitis is linked to Klebsiella--the evidence. Clin Rheumatol. 2007; 26(6): 858-64.
• 19. Spoorenberg A, van der Heijde D, de Klerk E, Dougados M. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 1999; 26(4): 980-4.
• 20. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, Landewé R, van ver Tempel H, Mielants H,et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003; 62(2):127-32.